UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH SEPTEMBER, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.1 pts less than Nifty Microcap 250 and 0.2 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Beryl Drugs reported weak Q2 FY26 results, with revenue from operations of Rs 561.42 lacs, a sharp drop of roughly 53% from Rs 1,193.25 lacs in the same quarter last year. The auditor flagged an Emphasis of Matter noting that part of the company's manufacturing facility remains under suspension and upgradation on a state FDA order, and production has not yet restarted because FDA inspection is still pending. For the quarter, profit after tax was a marginal Rs 0.89 lacs, translating to an EPS of just Rs 0.02, reflecting the hit from the production halt. For the half-year ended September 2025, total income stood at Rs 2,255.48 lacs but PAT was very thin. The company has been funding its plant upgradation through recoveries from debtors and overdraft, while operating cash flow remained positive at Rs 215.71 lacs.
The revenue collapse and ongoing FDA-linked production suspension are significant negatives that will weigh on near-term earnings and sentiment. Investors should track the FDA inspection outcome closely, as resumption of manufacturing is critical to recovering lost sales.